True DisCoVeRy of COVID-19 Disease Burden Versus Speculated Antiviral Cardiovascular Risk Requires a Control Group-Reference-Cited by-同舟云学术

True DisCoVeRy of COVID-19 Disease Burden Versus Speculated Antiviral Cardiovascular Risk Requires a Control Group

Published:2024-03-29 Issue:2 Volume:79 Page:392-394
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Gottlieb Robert L¹²³⁴^ORCID,Kalil Andre C⁵^ORCID

Affiliation:

1. Department of Internal Medicine, Baylor University Medical Center, Baylor Scott & White Health , Dallas, Texas , USA

2. Baylor Scott & White Research Institute , Dallas, Texas , USA

3. Department of Internal Medicine, Burnett School of Medicine at Texas Christian University (TCU) , Fort Worth, Texas , USA

4. Department of Internal Medicine, Texas A&M Health Science Center , Dallas, Texas , USA

5. Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae172/58364978/ciae172.pdf

Reference10 articles.

1. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics;Kalil;JAMA,2020

2. VV116 versus nirmatrelvir-ritonavir for oral treatment of COVID-19;Cao;N Engl J Med,2023

3. Cardiac adverse events and remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19): a post hoc safety analysis of the randomized DisCoVeRy trial;Terzić;Clin Infect Dis,2024

4. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19;Ader;Lancet Infect Dis,2022

5. Oral and intravenous 1′-cyano-substituted adenosine-like antivirals for early COVID-19;Gottlieb;Lancet Infect Dis,2024